Creative Touch Permanent Makeup and Aesthetics

Gluconolactone is a polyhydroxy acid (PHA) produced naturally by the oxidation of glucose, used topically for its four mechanistically distinct functions: calcium and magnesium chelation, surface exfoliation, humectancy, and antioxidant activity. Its chelating function is the most clinically specific – it binds divalent metal ions including the calcium and magnesium deposited by hard water, reducing mineral accumulation on the skin surface whilst simultaneously loosening corneodesmosomal adhesion through the same calcium sequestration mechanism that AHAs use. Multiple hydroxyl groups allow gluconolactone to attract and retain water molecules simultaneously with its exfoliating activity – an unusual combination for a chemical exfoliant. Its larger molecular size compared to glycolic or lactic acid limits penetration to the upper stratum corneum, producing substantially lower rates of erythema and irritation in sensitive and reactive presentations whilst delivering equivalent surface exfoliation outcomes at appropriate concentrations.

Gluconolactone sits in an unusual position among topical exfoliating acids. Most chemical exfoliants achieve their effect through a single primary mechanism – acid-mediated desquamation – and their tolerability profile is largely a function of concentration and pH. Gluconolactone achieves its effects through four distinct mechanisms operating simultaneously, and its tolerability advantage over glycolic or lactic acid is not simply a matter of lower acidity but of molecular size: its larger structure limits penetration depth, producing surface-limited activity rather than the deeper intercellular penetration that makes smaller AHA molecules effective and, in sensitive skin, reactive. ^[1]

Mechanism 1: Calcium chelation

Gluconolactone chelates divalent metal ions – calcium, magnesium, iron – by coordinating them within its lactone ring structure. This chelating activity operates at two distinct and clinically relevant levels in skin.

At the surface level, it binds calcium and magnesium deposits from hard water that have accumulated on the stratum corneum (SC) surface and within the superficial SC layers. Calcium stearate and magnesium stearate deposits – formed when hard water minerals react with skin surface fatty acids – raise surface pH, inhibit KLK5 and KLK7 enzyme activity, and disrupt the acid mantle environment. Gluconolactone’s chelation chemistry is well-characterised for divalent metal binding in vitro; direct clinical studies specifically measuring gluconolactone’s removal of hard water deposits from skin surface are limited, and this application is currently mechanistically derived rather than a directly studied clinical endpoint. It nonetheless represents a specific and non-duplicated function in a hard water barrier support protocol, and the chelation chemistry underpinning it is not in dispute.

At the corneodesmosomal level, calcium chelation reduces the calcium-dependent adhesion of DSG1 and DSC1 within corneodesmosomal complexes. This is the same pathway operative across the AHA/PHA class: electron microscopy studies on glycolic acid confirmed targeted breakdown of desmosomal attachment restricted to the stratum disjunctum, without disrupting the stratum compactum or lamellar lipid bilayers or increasing TEWL, via reduction of calcium ion concentration from cation-dependent cell adhesion molecules. Gluconolactone operates via this same class mechanism but with surface-limited penetration – producing controlled corneocyte release at the SC surface without the deeper layer disruption that smaller AHA molecules can cause. ^[2]

Mechanism 2: Surface-limited exfoliation

The AHA/PHA exfoliation mechanism shares a common pathway – calcium chelation loosening corneodesmosomal adhesion – but gluconolactone’s larger molecular structure fundamentally alters where along the SC depth this occurs. Glycolic acid (the smallest common AHA) penetrates readily into the mid-SC and can reach the SG–SC interface at higher concentrations. Gluconolactone’s multiple hydroxyl groups and larger molecular weight limit its penetration to the upper SC, producing corneocyte release at the surface without reaching deeper layers where structural disruption would impair barrier integrity. ^[4]

The clinical consequence: gluconolactone produces exfoliation with measurably lower rates of erythema, stinging, and photosensitisation than equivalent-strength AHA formulations in sensitive and reactive skin presentations. A 10% gluconolactone formulation consistently demonstrates skin-smoothing outcomes with tolerability profiles closer to non-acid moisturisers than to 10% glycolic acid formulations in comparative clinical work. For clients with rosacea, barrier-compromised atopic presentations, or post-procedure recovery, this tolerability profile matters more than the concentration figure alone. ^[3]

Mechanism 3: Humectancy

Unlike any AHA, gluconolactone carries multiple hydroxyl groups across its molecular structure – the same feature that limits its penetration depth also enables it to attract and retain water molecules within the upper SC. It functions as a humectant simultaneously with its exfoliating activity, reducing TEWL and increasing SC water content at concentrations where it is also producing measurable surface exfoliation. This dual activity is structurally unique to PHAs and not replicable with AHA formulations at equivalent exfoliation activity – adding a humectant to an AHA formulation addresses the two functions separately; gluconolactone achieves them from the same molecular action. ^[3]

A double-blind placebo-controlled trial in 40 males taking 2,000 mg/day dietary glucono-δ-lactone for six months confirmed significantly reduced TEWL, improved skin elasticity (Ua/Uf), and increased facial luminosity compared with placebo – establishing that gluconolactone’s barrier-supportive effects extend beyond topical surface-layer chemistry into systemic barrier function influence. ^[5]

The SC acidification produced by gluconolactone application additionally supports ceramide processing enzyme activity ( β-glucocerebrosidase and acid sphingomyelinase), confirming that its pH-lowering effect contributes to barrier lipid processing improvement independently of any direct synthesis effect.

Mechanism 4: Antioxidant activity and gene expression effects

Gluconolactone scavenges free radicals and chelates the iron and copper ions that catalyse hydroxyl radical formation via the Fenton reaction. In UV exposure models, gluconolactone provided up to 50% protection against UV-induced elastin promoter activation without increasing sunburn cell formation – distinguishing it from photosensitising AHAs and suggesting a photoprotective rather than photosensitising profile at therapeutic topical concentrations. ^[1]

A primary cell and gene expression study on a gluconolactone-based lotion confirmed upregulation of COL1A1 (type I collagen gene) and ELN (elastin gene) expression alongside involucrin upregulation, and a reduction in SA-β-galactosidase positive cells (a senescence marker) following UVB stimulation – confirmed across keratinocytes, fibroblasts, adipocytes, and sebocytes with a confirmed biosafety profile. MMP inhibition has been proposed as a further mechanism in review literature but is not yet confirmed in primary studies on gluconolactone specifically and is not cited here as a confirmed effect. ^[6]